The University of Colorado and Colorado State University are vying to become the first institution to build a carbon-ion radiotherapy research and treatment facility in the U.S. The treatment modality is available in Europe and Japan.
THE LEUKEMIA AND LYMPHOMA SOCIETY and OncoPep entered a partnership to advance an experimental cancer vaccine to treat patients with smoldering multiple myeloma, an asymptomatic stage of myeloma. The partnership is through the society's Therapy Acceleration Program.
DENOVO BIOPHARMA acquired enzastaurin from Eli Lilly and Co. Denovo gains all rights to develop, manufacture and commercialize enzastaurin globally, including transfer of all intellectual property and other rights, data, and information.
DAVID TWEARDY was named division head of internal medicine of MD Anderson Cancer Center effective Dec. 1.
SUTRO BIOPHARMA and the biopharmaceutical division of Merck KGaA in Darmstadt, Germany, which operates as EMD Serono in the U.S. and Canada, announced a collaboration and license agreement to develop antibody drug conjugates.
SOLIGENIX INC. reached an agreement with FDA on the design of a phase III clinical trial evaluating SGX301 (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma.
THE AMERICAN ASSOCIATION FOR CANCER RESEARCH is accepting submissions of ideas to two dream team grants: one offering $20 million for lung cancer research, and one for $6 million for ovarian cancer research.
BOEHRINGER INGELHEIM and CureVac announced an exclusive global license and development collaboration focused on CureVac's CV9202, a novel investigational therapeutic mRNA vaccine in early clinical development for the treatment of lung cancer.
The report is a “comprehensive educational tool that chronicles the progress that has been made against cancer…and calls on the administration and Congress to prioritize the growth of the NIH and NCI budgets,” according to AACR.
MEMORIAL SLOAN KETTERING CANCER CENTER began construction on a 285,000-square-foot outpatient cancer treatment facility in Middletown, N.J., with plans to open in late 2016.
